1. Volume 147, Issue 2, Pages 359-365.e1 (August 2014)
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection 
Pietro Andreone, Massimo G. Colombo, Jeffrey V. Enejosa, Iftihar Koksal, Peter Ferenci, Andreas Maieron, Beat Müllhaupt, Yves Horsmans, Ola Weiland, Henk W. Reesink, Lino Rodrigues, Yiran B. Hu, Thomas Podsadecki, Barry Bernstein 
Gastroenterology 
Volume 147, Issue 2, Pages e1 (August 2014)
DOI: /j.gastro
Copyright © 2014 AGA Institute Terms and Conditions

2. Figure 1
ITT genotype 1b efficacy subset treatment response over time. Percentage of patients achieving virologic response (±95% CIs) are presented for week 4 of treatment (RVR), end of treatment (EOTR), 4 weeks post-treatment (SVR4), and SVR12, as well as n/N within the bars graphs.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions

3. Supplementary Consort Flow Chart 1
Patient flow diagram.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions